Short Interest in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Expands By 7.3%

Amneal Pharmaceuticals, Inc. (NYSE:AMRXGet Rating) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 3,990,000 shares, a growth of 7.3% from the August 15th total of 3,720,000 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 3.9 days. Approximately 4.1% of the company’s shares are short sold.

Amneal Pharmaceuticals Stock Performance

Shares of NYSE:AMRX opened at $2.11 on Thursday. The company has a market cap of $640.44 million, a P/E ratio of -2.40, a PEG ratio of 0.14 and a beta of 1.29. The company has a debt-to-equity ratio of 15.38, a quick ratio of 1.03 and a current ratio of 1.56. Amneal Pharmaceuticals has a one year low of $2.10 and a one year high of $5.99. The business’s 50-day simple moving average is $2.48 and its 200 day simple moving average is $3.00.

Amneal Pharmaceuticals (NYSE:AMRXGet Rating) last announced its earnings results on Friday, August 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.03). Amneal Pharmaceuticals had a negative net margin of 6.29% and a positive return on equity of 56.26%. The company had revenue of $559.40 million for the quarter, compared to analysts’ expectations of $534.44 million. During the same quarter in the previous year, the business posted $0.23 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, sell-side analysts forecast that Amneal Pharmaceuticals will post 0.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group reduced their price objective on Amneal Pharmaceuticals from $4.50 to $4.00 and set a “buy” rating on the stock in a research note on Monday, August 8th. TheStreet downgraded Amneal Pharmaceuticals from a “c-” rating to a “d+” rating in a report on Friday, August 12th. Finally, StockNews.com downgraded Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 24th.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Covestor Ltd purchased a new stake in Amneal Pharmaceuticals during the 4th quarter worth approximately $32,000. First Quadrant LLC CA purchased a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $37,000. O Shaughnessy Asset Management LLC purchased a new stake in Amneal Pharmaceuticals during the 2nd quarter worth approximately $37,000. Running Point Capital Advisors LLC purchased a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $42,000. Finally, Meeder Asset Management Inc. purchased a new stake in Amneal Pharmaceuticals during the 1st quarter worth approximately $62,000. 32.93% of the stock is currently owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

(Get Rating)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Recommended Stories

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.